Judge Dismissed Securities Lawsuit Against Regeneron
The U.S. District Court ruled that Regeneron Pharmaceuticals statements on Eylea sales amounted to corporate puffery.
Updated on Sept. 21, 2026 in Public Companies
Live Poll
Should pharmaceutical companies be held legally liable for marketing claims that shape investor expectations?
Judge Mary Kay Vyskocil dismissed a proposed class-action securities fraud lawsuit filed against Regeneron Pharmaceuticals. Investors had alleged the company intentionally overhyped sales of its eye treatment drug Eylea.
Why it matters
The ruling clarifies that companies are permitted to tout drug effectiveness in public statements without being required to disclose every factor that might influence market success.
The U.S. District Court for the Southern District of New York oversaw this class-action filing, which centered on claims that Regeneron excluded credit card fee reimbursements from federal price reporting.
The players
Mary Kay Vyskocil
She is a judge serving on the U.S. District Court for the Southern District of New York who presided over this case.
Regeneron Pharmaceuticals
This is a biotechnology company that develops and markets medicines including the eye treatment drug Eylea.
The details
The lawsuit claimed Regeneron misled investors by omitting the reimbursement of credit card fees from its price reports to federal regulators. However, the court determined that the company's statements regarding enthusiasm for Eylea constituted protected corporate puffery rather than actionable fraud.
Timeline
September 21, 2026: The U.S. District Court dismissed the proposed class-action lawsuit.
Market Landscape
The ruling reinforces established standards under the Private Securities Litigation Reform Act of 1995 regarding corporate disclosure expectations. This decision limits the scope for future securities litigation by protecting companies from liability for broad statements of enthusiasm about their products.
The decision provides clarity for retail and institutional investors regarding how to interpret company-issued performance projections. Shareholders should note that broad corporate optimism is legally distinct from verifiable financial reporting under current securities law.
The takeaway
The court's decision establishes that companies are not required to disclose every operational nuance when promoting the success of a product. Investors should conduct independent due diligence rather than relying on high-level executive enthusiasm as an indicator of financial performance.
Further reading
For more on industry litigation and regulatory challenges, see Public Companies.
Live Poll
Should pharmaceutical companies be held legally liable for marketing claims that shape investor expectations?
